EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum and Liver Lipidome Following Empagliflozin Administration for Six Months in a Fast Food Diet Mouse Model

Evangelia S Makri iD, Thomai Mouskeftara, Helen Gika iD, Konstantinos Xanthopoulos iD, Eleftheria Makri iD, Panagiotis Mavrommatis-Parasidis iD, Anastasia Tsingotjidou iD, Angeliki Cheva, Antonis Goulas, Stergios A Polyzos iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26199273 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Evangelia S Makri und 9 weiteren Autor:innen. Beteiligte Einrichtung: First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Liver, Lipid Metabolism. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Empagliflozin is a sodium–glucose co-transporter inhibitor approved for the treatment of type 2 diabetes mellitus. The aim of this study was the 6-month effect of empagliflozin on serum and liver lipidome in C57BL/6J mice fed on a fast food diet (FFD). Three groups were studied; two of them fed on FFD, one with empagliflozin (EMPA group), and another without empagliflozin (FFD group); the third group fed on a chow diet and served as the control group (CD group). Following untargeted lipidomic analysis, the FFD and EMPA groups displayed largely similar serum lipid profiles, characterized by elevated levels in the majority of identified lipids, compared with the CD group, particularly glycerophospholipids. For instance, phosphatidylcholine (PC) 34:1 and phosphatidylinositol (PI) 38:3 increased in the FFD compared with the CD group (both p < 0.001, fold change 2.4 and 17.6, respectively) with comparable increases observed in the EMPA group. Hepatic lipid profiles varied more significantly between groups. For example, PC 34:1 was increased in the FFD and in the EMPA compared with the CD group (both p < 0.001, fold change 1.7 and 1.6, respectively), whereas PC 32:0 was decreased in the FFD group and in the EMPA group compared with the CD group (both p < 0.001, fold change 0.6 and 0.5, respectively). FFD appears to have a more substantial impact on lipidomic profiles compared with the preventive empagliflozin effect. Notably, the concentration of lysophosphatidylcholine (LPC) 22:6 was significantly reduced in the EMPA compared with the FFD group (p < 0.001, fold change 1.4). Interestingly, several glycerophospholipids, including PC 34:1, PC 35:1, PC 36:3, PC 38:4, PI 34:2 and PI 38:3, increased in both serum and hepatic tissues of the FFD and EMPA groups compared with the CD group. In conclusion, limited differences in the lipidomic profile were observed in the EMPA compared with the FFD group (e.g., LPC 22:6). However, both the EMPA and FFD groups showed distinct lipidomic profiles compared with the CD group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesLiverLipid MetabolismLipidsSodium-Glucose Transporter 2 InhibitorsAnimalsMiceLipidomicsMice, Inbred C57BLMaleDisease Models, AnimalDiabetes Mellitus, Type 2

Stichwörter der Autor:innen

empagliflozinfast food diethepatic steatosismetabolic dysfunction-associated steatotic liver diseasemouse modelnonalcoholic fatty liver diseaseuntargeted lipidomics

Substanzen

Benzhydryl CompoundsempagliflozinGlucosidesLipidsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
  • Laboratory of Forensic Medicine & Toxicology, Department of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
  • Biomic AUTh, Center for Interdisciplinary Research and Innovation (CIRI-AUTH), Balkan Center B1.4, 57001 Thessaloniki, Greece.
  • Laboratory of Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
  • Institute of Applied Biosciences, Centre for Research and Technology, 57001 Thessaloniki, Greece.
  • Laboratory of Anatomy, Histology & Embryology, School of Veterinary Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.

ORCID-Profile: Evangelia S Makri, Helen Gika, Konstantinos Xanthopoulos, Eleftheria Makri, Panagiotis Mavrommatis-Parasidis, Anastasia Tsingotjidou, Stergios A Polyzos

Zitieren

APA

Makri, E. S., Mouskeftara, T., Gika, H., Xanthopoulos, K., Makri, E., Mavrommatis-Parasidis, P., Tsingotjidou, A., Cheva, A., Goulas, A., & Polyzos, S. A. (2025). Serum and Liver Lipidome Following Empagliflozin Administration for Six Months in a Fast Food Diet Mouse Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199273

Vancouver

Makri ES, Mouskeftara T, Gika H, Xanthopoulos K, Makri E, Mavrommatis-Parasidis P, et al. Serum and Liver Lipidome Following Empagliflozin Administration for Six Months in a Fast Food Diet Mouse Model. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199273

BibTeX
@article{Makri2025,
  author = {Makri, Evangelia S and Mouskeftara, Thomai and Gika, Helen and Xanthopoulos, Konstantinos and Makri, Eleftheria and Mavrommatis-Parasidis, Panagiotis and Tsingotjidou, Anastasia and Cheva, Angeliki and Goulas, Antonis and Polyzos, Stergios A},
  title = {Serum and Liver Lipidome Following Empagliflozin Administration for Six Months in a Fast Food Diet Mouse Model},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26199273}
}
Kostenlos starten →